10 results about "Animal cell line" patented technology

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

The application belongs to the field of microbial animal cell lines, and relates to a human immortalized simple renal cyst cell line SRC-X1 and an application thereof. The human immortalized simple renal cyst cell line is named SRC-X1, the cell line has been preserved in the China Center for Type Culture Collection on September 19, 2025, and the preservation number is CCTCC NO: C2025303. The application of the human immortalized simple renal cyst cell line SRC-X1 in preparation, screening or evaluation of renal cyst treatment drugs. The application of the human immortalized simple renal cyst cell line SRC-X1 as a renal cyst cell model. The application of the human immortalized simple renal cyst cell line SRC-X1 as experimental material in renal cyst basic or clinical research.

The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.

This invention relates to synthetic biology, gene and cell therapy, and particularly to a gene translation system regulated by non-natural amino acids and its applications. This gene translation system precisely regulates gene expression initiation using non-natural amino acids. The invention also provides eukaryotic expression vectors, mammalian cell lines, microcapsules, vacuum fiber tubes, and non-natural amino acid cookies containing the aforementioned gene translation system. Furthermore, this invention discloses that the multifunctional platform can precisely regulate insulin expression and release for diabetes treatment; this gene expression regulation platform can be used to construct complex biological computer-controlled systems. This invention provides a powerful new gene expression regulation tool for gene therapy and cell therapy.

The application discloses a method for continuous editing of multi-site chromosomes in eukaryotic cells. The application provides a method for integrating the genome of eukaryotic cells, comprising: using a knock-in site-specific recombination site (such as noxM) in the genome of eukaryotic cells, realizing integration of a large fragment circular DNA molecule at a specific site of the genome under the action of a knock-in site-specific recombinase (such as Nigri), and simultaneously using an adjacent knock-out site-specific recombination site (such as loxP or a mutant thereof), rearranging the related sites under the action of a knock-out site-specific recombinase (such as Cre), so as to realize continuity of integration. The novel editing platform of high-efficiency site-specific recombination provided by the application can realize directional, continuous and multi-site integration of a large fragment DNA in eukaryotic cells, and the application has important application prospects in the field of biological technologies including plant breeding, animal cell line development, fungus engineering and the like.

Novel gene repressor systems are provided that are useful in animal cells that include engineered repressors with altered ligand-binding domains (LBDs) and DNA-binding domains (DBDs), as well as mutated operator sequences. In one aspect, the systems enable independent, drug-inducible control of multiple genes within a single animal or animal cell line. In one aspect, the disclosure provides both tetracycline-responsive repressors and sulfonylurea (SU)-responsive repressors — e.g., variants that respond specifically to ethametsulfuron-methyl (Es) or chlorsulfuron (Cs). Mutations are introduced to either the LBD (to alter ligand specificity), DBD (to alter operator binding), or the operator sequence itself, resulting in orthogonal systems.

The application discloses a human ampullary carcinoma cell line DPC-X5 and an application thereof, and belongs to the field of microbial animal cell lines. The human ampullary carcinoma cell line is named as a human ampullary carcinoma cell line (homo sapiens) DPC-X5, has been preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human ampullary carcinoma cell line DPC-X5 can be applied to the establishment of a cell model of ampullary carcinoma occurrence, development or metastasis. The human ampullary carcinoma cell line DPC-X5 can be applied to the research of a cell model of differentiation mechanism, cell morphology and functional abnormality, tumor infiltration and metastasis mechanism of ampullary carcinoma and guidance of clinical comprehensive diagnosis and treatment. The human ampullary carcinoma cell line DPC-X5 can be applied to the research of an occurrence mechanism of ampullary carcinoma and screening of drugs for preventing and treating ampullary carcinoma. The human ampullary carcinoma cell line DPC-X5 can be applied to the establishment of an animal model of ampullary carcinoma.

The present invention relates to a method comprising the steps of a) contacting ex vivo a cell from a mammalian cell line capable of secreting cytokines in a liquid medium with a set of antibodies from a blood sample from a mammalian subject which is known to be healthy or to suffer from a first disease; b) detecting the level of at least one cytokine present in the liquid medium following step a); c) contacting ex vivo a cell from the mammalian cell line capable of secreting cytokines with a set of antibodies from a blood sample from a mammalian reference subject which is known to be healthy or to suffer from a second disease in a liquid medium; d) detecting the level of the at least one cytokine present in the liquid medium following step c); e) determining a cytokine signature by determining the difference between the level of the at least one cytokine determined in step b) and the level of the at least one cytokine determined in step d), wherein the method is a method for aiding in detecting or diagnosing a disease, a method for aiding in distinguishing between a first disease and a second disease, or a method for aiding in diagnosing whether a mammalian subject is likely to suffer from a disease.

Development of media and feeds for CHO cells The present invention provides a DNA array-based method for assessing the effect of at least one test component of a cell culture medium on at least one phenotype of interest in a test mammalian cell line cultured in the cell culture medium comprising the test component, comprising: (a) measuring a test methylation profile of one or more preselected methylation sites within the DNA of a test cell line; (b) comparing the test methylation profile obtained from (a) with at least one control methylation profile obtained from the same mammalian cell line cultured in a cell culture medium that does not contain the test component. and a significant similarity between the test methylation profile and the control methylation profile in (a) indicates that the test cell has the phenotype of interest and that the test component does not affect the phenotype of interest; a significant difference between the test methylation profile of (a) and the control methylation profile indicates that the test cell has a phenotype of interest and that the test component affects the phenotype of interest; (c) The test methylation profile obtained from (a) (i) at least one first control methylation profile obtained from a first mammalian control cell line exhibiting at least one phenotype of interest; and / or (ii) at least one second control methylation profile obtained from a second mammalian control cell line that does not exhibit the phenotype of interest; Process to compare with and The control cell line was not in contact with the test component. a significant similarity between the test methylation profile of (a) and the first or second control methylation profile indicates that the test cell has a phenotype of interest or does not have a phenotype of interest, respectively; wherein a difference between the test methylation profile of (a) and the first or second control methylation profile indicates that the test cell does not have a phenotype of interest or that the test cell has a phenotype of interest.

The invention discloses a human pancreatic cancer cell line PDAC-X6 and application thereof, and belongs to the field of microbial animal cell lines. The human pancreatic cancer cell line is named as a human pancreatic cancer cell line PDAC-X6 homo sapiens, and is preserved in the China Center for Type Culture Collection on November 22, 2025, and the preservation number is CCTCC NO: C2025355. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a cell model for occurrence, development or metastasis of pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to cell models for studying the differentiation mechanism, cell morphology and dysfunction and tumor infiltration and metastasis mechanism of pancreatic cancer and guiding clinical comprehensive diagnosis and treatment. The human pancreatic cancer cell line PDAC-X6 can be applied to research on the occurrence mechanism of pancreatic cancer and screening of drugs for preventing and treating pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a pancreatic cancer animal model.